Рецепт. 2018; : 565-571
СилваДепрекс: фармакологические особенности фитокомпозиции для поддержания нормального функционального состояния нервной системы
Аннотация
СилваДепрекс – комбинированный растительный препарат. В его состав входят экстракты 6 видов растений: зверобоя продырявленного, родиолы розовой, валерианы лекарственной, володушки серповидной, муира пуама, красного клевера. Препарат повышает стрессоустойчивость, улучшает когнитивные функции, корригирует эмоциональный фон, что снижает тревожность, устраняет беспокойство и нормализует сон. Антидепрессивное действие препарата СилваДепрекс подтверждено результатами клинического исследования. При этом он малотоксичен и противопоказан лишь при индивидуальной непереносимости компонентов препарата, беременности и грудном вскармливании. Достоинством препарата является и то, что, в отличие от большинства рецептурных нейротропных лекарственных средств, СилваДепрекс не влияет на способность к управлению транспортными средствами.
Список литературы
1. Srole L. et al. (1962) Mental health in Metropolis, the Midtown Manhattan Study, vol. I.
2. Emeliantseva T.A. (2006) Nevrozogenez (multimodalnyy podkhod): metod. rekomendatsii [Neurogenesis (multimodal approach): method. recommendations]. Minsk: BGMU. (in Russian).
3. Shilova O.V., Khmara N.V. (2007) Osnovy obshchey i chastnoy psikhiatrii i narkologii: ucheb.-metod. posobiye k prakticheskim zanyatiyam po psikhiatrii i narkologii dlya studentov lechebnogo fakulteta [Elements of general and partial psychiatry and narcology: educ.-method. materials for practical classes in psychiatry and narcology for students of the Faculty of General Medicine]. Gomel: UO «GomGMU». (in Russian).
4. Krapivkin A.I. (2009) Ratsionalnaya fi toterapiya nevroticheskikh rasstroystv u detey [Rational phytotherapy of neurotic disorders in children]. Praktika pediatra, vol. 5, pp. 33–36.
5. Syropyatov O.G., Dzeruzhinskaya N.A. (2017) Fitoterapiya psikhosomaticheskikh rasstroystv [Phytotherapy of psychosomatic disorders]. Moskva: Litres. (in Russian).
6. Turishchev S.N. (2005) Fitoterapiya dlya vsekh [Phytotherapy for all]. Moskva: Olma-Press Invest. (in Russian).
7. Smulevich A.B. (2001) Depressii v obshchey meditsine. Rukovodstvo dlya vrachey [Depression in general medicine. A guide for doctors]. Moskva: Meditsinskoye informatsionnoye agentstvo. (in Russian).
8. SilvaDepreks – biologicheski-aktivnay dobavka k pishche [SilvaDepreks, a biologically active food additive]. Certifi cate of state registration No. KZ. 16.01.78.003.Е.004384.04.15 of 04/07/2015.
9. Pūce S. (2016) Otsenka preparata SilvaDeprex u patsiyentov s depressivnymi rasstroystvami v parallelnykh gruppakh [Evaluation of SilvaDeprex in patients with depressive disorders in parallel groups]. Latvijas ārsts, vol. 3, pp. 72–77.
10. Klinicheskiy protokol «Okazaniye meditsinskoy pomoshchi patsiyentam s psikhicheskimi i povedencheskimi rasstroystvami» ["Provision of medical care to patients with mental and behavioral disorders"]. Prilozheniye k prikazu MZ RB ot 31 dekabrya 2010 g. № 1387.
11. Essential Medicines and Health Products Information Portal A World Health. Organization resource. Available at: http://apps.who.int/medicinedocs/en/d/Js17534en/. 02.02.2018 (unpublished).
12. EMA Assessment Report on Hypericum perforatum L. herba – European Medicines Agency Monograph. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2010/01/WC500059144.pdf. 02.02.2018 (unpublished).
13. European Medicines Agency Monograph. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/herbal_search.jsp&mid=WC0b01ac058001fa1d. 02.02.2018 (unpublished).
14. Treiber K., Singer A. (2005) Hyperforin activates nonselective cation channels (NSCCs). British Journal of Pharmacology, vol. 145, pp. 75–83.
15. Anghelescu I.G., Kohnen R., Szegedi A., Klement S., Kieser M. (2006) Comparison of hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. Pharmacopsychiatry, vol. 39, no 6, pp. 213–219.
16. Behnke K., Jensen G.S., Granbanm P.I., Gruenwald J. (2002) Hypericum perforatum versus fl uoxetine in the treatment of mild to moderate depression. Adv Ther, vol. 19, no 1, pp. 43–52.
17. Bjerkenstedt L., Edman G.V., Aiken R.G., Mannel M. (2005) Hypericum extract LI 160 and fl uoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci, vol. 255, no 1, pp. 40–47.
18. Linde K., Berner M., Egger M (2005) Mulrow C. St John’s wort for depression. British Journal of Psychiatry, vol. 186, pp. 99–107.
19. Barnes J., Anderson A., Phillipson J.D. (2001) St John’s Wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. JPP, vоl. 53, pp. 583–600.
20. Kasper S., Anghelescu I.G., Szegedi A., Dienel A., Kieser M. (2006) Superior effi cacy of St John’s wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebocontrolled, multi-center trial. ВМС Medicine, vol. 4, pp. 14–27.
21. Kaufman J.H., Cannon-Smith T. (2007) Improved ejaculatory control and sexual satisfaction in pilot study of men taking Hypericum perforatum extract. Internet J Nutr Wellness, vol. 3. p. 2.
22. Wheatley D. (1999) Hypericum in seasonal aff ective disorder (SAD). Current medical research and opinion, vol. 15, no 1, pp. 33–37.
23. ЕМА Assessment Report on Rhodiola rosea radix. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/ 2011/09/WC500112675.pdf. 02.02.2018.
24. Panossian A., Wikmcm G., Sairis J. Rosenroot (2010) Rhodiola rosea: traditional use, chemical composition, pharmacology and clinical effi cacy. Phytomedicine, vol. 17, pp. 481–493.
25. Van Diermen D., Mansion Bravo J., Reisi M., Corrupt P.A., Hostettmann K. (2009) Monoamine oxidase inhibition by Rhodiola rosea L. roots. Journal of Ethnopharmacology, vol. 122, pp. 397–401.
26. Darbinyan V., Aslanyan G., Amroyan E., Gabrielyan E., Malms from C, Panossian A. (2007) Clinical trial of Rhodiola rosea L. extract SITR-5 in the treatment of mild to moderate depression. Nord J Psychiatry, vol. 61, no 5, pp. 343–348.
27. Sheng Q.S., Wang Z.J., Zhang J., Zhang Y.G. (2013) Saliclroside promotes peripheral nerve regeneration following crush injury to the sciatic nerve in rats. Neuroreport, vol. 24, no 5, pp. 217–223.
28. Fintelmann V., Griienwcild J. (2007) Effi cacy and tolerability of a Rhodiola roseci extract in adults with physical and cognitive defi ciencies. Adv Ther, vol. 24, no 4, pp. 929–939.
29. List of references supporting the assessment of Valeriana offi cinalis L., radix and Valeriana offi cinalis L., aetheroleum. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_List_of_references_supporting_the_assessment_report/2015/07/WC500190428.pdf. 02.02.2018.
30. ЕМА Assessment Report on Valeriana offi cinalis (L.), radix. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_List_of_references_supporting_the_assessment_report/2015/07/WC500190428.pdf. 02.02.2018.
31. Houghton Р.J. (1999) The scientifi c basis for the reputed activity of valerian. J Pharm Pharmacol, vol. 51, no 5, pp. 505–512.
32. Salter S., Brownie S. (2010) Treating primary insomnia. The effi cacy of valerian and hops. Australian Family Physician, vol. 39, no 6, pp. 433–437.
33. Fernandez-San-Martin M., Masci-Font R., Palacios-Soler L, Sancho-Gomez P., Calbo-Caldentey C., Flores-Mateo G. (2010) Eff ectiveness of valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med, vol. 11, no 6, pp. 505–511.
34. Kuang P.I., Sun S., Yang B., Xia Y., Feng W. (2009) New megastigmane sesquiterpene and indole alkaloid glucosides from the aerial parts of Bupleurum chinense DC. Fitoterapia, vol. 80, no 1, pp. 35–38.
35. Li X., Jia Y., Song A., Chen X., Bi K. (2005) Analysis of the essential oil from radix bupleuri using capillary gas chromatography, Yakugaku Zasshi, vol. 125, no 10, pp. 815–819.
36. Xie Y., Lu W., Cao S., Jiang X., Yin M., Tang W. (2006) Preparation of bupleurum nasal spray and evaluation on its safety and effi cacy. Chem Pharm Bull, vol. 54, no 1, pp. 48–53.
37. Lee В.B., Yun I.P.Y., Shim I.S., Lee P.I.J., Hahm D.P.I. (2012) Bupleurum falcatum prevents depression and anxiety-like behaviors in rats exposed to repeated restraint stress. Journal of Microbiology and Biotechnology, vol. 22, no 3, pp. 422–430.
38. Shamloul R. (2010) Natural aphrodisiacs. J Sex Med, vol. 7, no 1, pp. 39–49.
39. Tang W., Hioki H., Наrada К., Kubo М., Fukuyama Y. (2008) Clerodane diterpenoids with NGF-potentiating activity from Ptychopetalum olacoides. J Nat Prod, vol. 71, no 10, pp. 1760–1763.
40. Tang W., Kubo M., Haradci K., Hioki H., Fukuyama Y. (2009) Novel NGF-potentiating diterpenoids from a Brazilian medicinal plant, Ptychopetalum olacoides. Bioorg Med Chem Lett, vol. 19, no 3, pp. 882–886.
41. Tang W., Harcida K., Kubo M., Hioki H., Fukuyama Y. (2011) Eight new clerodane diterpenoids from the bark of Ptychopetalum olacoides. Nat Prod Commun, vol. 6, no 3, pp. 327–332.
42. Figueiro P.L., Ilhci J., Pochmcmn I., Porciuncula L.O., Xavier L.L., Achaval P.L., Nunes S., Elisabetsky E. (2010) Acetylcholinesterase inhibition in cognition-relevant brain areas of mice treated with a nootropic Amazonian herbal (Muira puama). Phytomedicine, vol. 17, pp. 956–962.
43. Piato A.L, Detanico В.C., Line V.M., Herrmann A.P., Nunes D.S., Elisabetsky E. (2010) Anti-stress eff ects of the "tonic" Ptychopetalum olacoides. Phytomedicine, vol. 17, pp. 248–253.
44. Siqueira I.R., Cimarosti H., Fochesatto C., Nunes D.S., Salbego C., Elisabetsky E., Netto C.A. (2004) Neuroprotective eff ects of Ptychopetalum olacoides Bentham (Olacaceae) on oxygen and glucose deprivation induced damage in rat hippocampal slices. Life Sciences, vol. 75, pp. 1897–1906.
45. Murray М. (1994) Yohimbine vs Muira puama in the treatment of erectile dysfunction. The American Journal of Natural Medicine, vol. 1, no 3, p. 8.
46. Beck V., Rohr U., Jim A. (2005) Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy. J Steroid Biochem Mol Biol, vol. 94, no 5, pp. 499–518.
Recipe. 2018; : 565-571
SilvaDeprex: pharmacological features of phytocomposition for maintaining of normal functional state of nervous system
Abstract
SilvaDeprex is a combined herbal drug: St. John’s Wort, Rhodiola, Valerian, Volodushka, Muira Puama, Red Clover. These compounds increase stress resistance, correct emotional background, reduce anxiety, normalize sleep and improve cognitive functions. It is confi rmed in clinical trial that SilvaDeprex has antidepressant eff ect. In addition, it is established that SilvaDeprex improves sleep, reduces fatigue and lack of energy. Contraindications are standard, as for all phytopreparations: individual intolerance of components, pregnancy and lactation. It is important that, unlike most prescription neurotropic drugs, SilvaDeprex is not contraindicated to drivers.
References
1. Srole L. et al. (1962) Mental health in Metropolis, the Midtown Manhattan Study, vol. I.
2. Emeliantseva T.A. (2006) Nevrozogenez (multimodalnyy podkhod): metod. rekomendatsii [Neurogenesis (multimodal approach): method. recommendations]. Minsk: BGMU. (in Russian).
3. Shilova O.V., Khmara N.V. (2007) Osnovy obshchey i chastnoy psikhiatrii i narkologii: ucheb.-metod. posobiye k prakticheskim zanyatiyam po psikhiatrii i narkologii dlya studentov lechebnogo fakulteta [Elements of general and partial psychiatry and narcology: educ.-method. materials for practical classes in psychiatry and narcology for students of the Faculty of General Medicine]. Gomel: UO «GomGMU». (in Russian).
4. Krapivkin A.I. (2009) Ratsionalnaya fi toterapiya nevroticheskikh rasstroystv u detey [Rational phytotherapy of neurotic disorders in children]. Praktika pediatra, vol. 5, pp. 33–36.
5. Syropyatov O.G., Dzeruzhinskaya N.A. (2017) Fitoterapiya psikhosomaticheskikh rasstroystv [Phytotherapy of psychosomatic disorders]. Moskva: Litres. (in Russian).
6. Turishchev S.N. (2005) Fitoterapiya dlya vsekh [Phytotherapy for all]. Moskva: Olma-Press Invest. (in Russian).
7. Smulevich A.B. (2001) Depressii v obshchey meditsine. Rukovodstvo dlya vrachey [Depression in general medicine. A guide for doctors]. Moskva: Meditsinskoye informatsionnoye agentstvo. (in Russian).
8. SilvaDepreks – biologicheski-aktivnay dobavka k pishche [SilvaDepreks, a biologically active food additive]. Certifi cate of state registration No. KZ. 16.01.78.003.E.004384.04.15 of 04/07/2015.
9. Pūce S. (2016) Otsenka preparata SilvaDeprex u patsiyentov s depressivnymi rasstroystvami v parallelnykh gruppakh [Evaluation of SilvaDeprex in patients with depressive disorders in parallel groups]. Latvijas ārsts, vol. 3, pp. 72–77.
10. Klinicheskiy protokol «Okazaniye meditsinskoy pomoshchi patsiyentam s psikhicheskimi i povedencheskimi rasstroystvami» ["Provision of medical care to patients with mental and behavioral disorders"]. Prilozheniye k prikazu MZ RB ot 31 dekabrya 2010 g. № 1387.
11. Essential Medicines and Health Products Information Portal A World Health. Organization resource. Available at: http://apps.who.int/medicinedocs/en/d/Js17534en/. 02.02.2018 (unpublished).
12. EMA Assessment Report on Hypericum perforatum L. herba – European Medicines Agency Monograph. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2010/01/WC500059144.pdf. 02.02.2018 (unpublished).
13. European Medicines Agency Monograph. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/herbal_search.jsp&mid=WC0b01ac058001fa1d. 02.02.2018 (unpublished).
14. Treiber K., Singer A. (2005) Hyperforin activates nonselective cation channels (NSCCs). British Journal of Pharmacology, vol. 145, pp. 75–83.
15. Anghelescu I.G., Kohnen R., Szegedi A., Klement S., Kieser M. (2006) Comparison of hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. Pharmacopsychiatry, vol. 39, no 6, pp. 213–219.
16. Behnke K., Jensen G.S., Granbanm P.I., Gruenwald J. (2002) Hypericum perforatum versus fl uoxetine in the treatment of mild to moderate depression. Adv Ther, vol. 19, no 1, pp. 43–52.
17. Bjerkenstedt L., Edman G.V., Aiken R.G., Mannel M. (2005) Hypericum extract LI 160 and fl uoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci, vol. 255, no 1, pp. 40–47.
18. Linde K., Berner M., Egger M (2005) Mulrow C. St John’s wort for depression. British Journal of Psychiatry, vol. 186, pp. 99–107.
19. Barnes J., Anderson A., Phillipson J.D. (2001) St John’s Wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. JPP, vol. 53, pp. 583–600.
20. Kasper S., Anghelescu I.G., Szegedi A., Dienel A., Kieser M. (2006) Superior effi cacy of St John’s wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebocontrolled, multi-center trial. VMS Medicine, vol. 4, pp. 14–27.
21. Kaufman J.H., Cannon-Smith T. (2007) Improved ejaculatory control and sexual satisfaction in pilot study of men taking Hypericum perforatum extract. Internet J Nutr Wellness, vol. 3. p. 2.
22. Wheatley D. (1999) Hypericum in seasonal aff ective disorder (SAD). Current medical research and opinion, vol. 15, no 1, pp. 33–37.
23. EMA Assessment Report on Rhodiola rosea radix. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/ 2011/09/WC500112675.pdf. 02.02.2018.
24. Panossian A., Wikmcm G., Sairis J. Rosenroot (2010) Rhodiola rosea: traditional use, chemical composition, pharmacology and clinical effi cacy. Phytomedicine, vol. 17, pp. 481–493.
25. Van Diermen D., Mansion Bravo J., Reisi M., Corrupt P.A., Hostettmann K. (2009) Monoamine oxidase inhibition by Rhodiola rosea L. roots. Journal of Ethnopharmacology, vol. 122, pp. 397–401.
26. Darbinyan V., Aslanyan G., Amroyan E., Gabrielyan E., Malms from C, Panossian A. (2007) Clinical trial of Rhodiola rosea L. extract SITR-5 in the treatment of mild to moderate depression. Nord J Psychiatry, vol. 61, no 5, pp. 343–348.
27. Sheng Q.S., Wang Z.J., Zhang J., Zhang Y.G. (2013) Saliclroside promotes peripheral nerve regeneration following crush injury to the sciatic nerve in rats. Neuroreport, vol. 24, no 5, pp. 217–223.
28. Fintelmann V., Griienwcild J. (2007) Effi cacy and tolerability of a Rhodiola roseci extract in adults with physical and cognitive defi ciencies. Adv Ther, vol. 24, no 4, pp. 929–939.
29. List of references supporting the assessment of Valeriana offi cinalis L., radix and Valeriana offi cinalis L., aetheroleum. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_List_of_references_supporting_the_assessment_report/2015/07/WC500190428.pdf. 02.02.2018.
30. EMA Assessment Report on Valeriana offi cinalis (L.), radix. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_List_of_references_supporting_the_assessment_report/2015/07/WC500190428.pdf. 02.02.2018.
31. Houghton R.J. (1999) The scientifi c basis for the reputed activity of valerian. J Pharm Pharmacol, vol. 51, no 5, pp. 505–512.
32. Salter S., Brownie S. (2010) Treating primary insomnia. The effi cacy of valerian and hops. Australian Family Physician, vol. 39, no 6, pp. 433–437.
33. Fernandez-San-Martin M., Masci-Font R., Palacios-Soler L, Sancho-Gomez P., Calbo-Caldentey C., Flores-Mateo G. (2010) Eff ectiveness of valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med, vol. 11, no 6, pp. 505–511.
34. Kuang P.I., Sun S., Yang B., Xia Y., Feng W. (2009) New megastigmane sesquiterpene and indole alkaloid glucosides from the aerial parts of Bupleurum chinense DC. Fitoterapia, vol. 80, no 1, pp. 35–38.
35. Li X., Jia Y., Song A., Chen X., Bi K. (2005) Analysis of the essential oil from radix bupleuri using capillary gas chromatography, Yakugaku Zasshi, vol. 125, no 10, pp. 815–819.
36. Xie Y., Lu W., Cao S., Jiang X., Yin M., Tang W. (2006) Preparation of bupleurum nasal spray and evaluation on its safety and effi cacy. Chem Pharm Bull, vol. 54, no 1, pp. 48–53.
37. Lee V.B., Yun I.P.Y., Shim I.S., Lee P.I.J., Hahm D.P.I. (2012) Bupleurum falcatum prevents depression and anxiety-like behaviors in rats exposed to repeated restraint stress. Journal of Microbiology and Biotechnology, vol. 22, no 3, pp. 422–430.
38. Shamloul R. (2010) Natural aphrodisiacs. J Sex Med, vol. 7, no 1, pp. 39–49.
39. Tang W., Hioki H., Narada K., Kubo M., Fukuyama Y. (2008) Clerodane diterpenoids with NGF-potentiating activity from Ptychopetalum olacoides. J Nat Prod, vol. 71, no 10, pp. 1760–1763.
40. Tang W., Kubo M., Haradci K., Hioki H., Fukuyama Y. (2009) Novel NGF-potentiating diterpenoids from a Brazilian medicinal plant, Ptychopetalum olacoides. Bioorg Med Chem Lett, vol. 19, no 3, pp. 882–886.
41. Tang W., Harcida K., Kubo M., Hioki H., Fukuyama Y. (2011) Eight new clerodane diterpenoids from the bark of Ptychopetalum olacoides. Nat Prod Commun, vol. 6, no 3, pp. 327–332.
42. Figueiro P.L., Ilhci J., Pochmcmn I., Porciuncula L.O., Xavier L.L., Achaval P.L., Nunes S., Elisabetsky E. (2010) Acetylcholinesterase inhibition in cognition-relevant brain areas of mice treated with a nootropic Amazonian herbal (Muira puama). Phytomedicine, vol. 17, pp. 956–962.
43. Piato A.L, Detanico V.C., Line V.M., Herrmann A.P., Nunes D.S., Elisabetsky E. (2010) Anti-stress eff ects of the "tonic" Ptychopetalum olacoides. Phytomedicine, vol. 17, pp. 248–253.
44. Siqueira I.R., Cimarosti H., Fochesatto C., Nunes D.S., Salbego C., Elisabetsky E., Netto C.A. (2004) Neuroprotective eff ects of Ptychopetalum olacoides Bentham (Olacaceae) on oxygen and glucose deprivation induced damage in rat hippocampal slices. Life Sciences, vol. 75, pp. 1897–1906.
45. Murray M. (1994) Yohimbine vs Muira puama in the treatment of erectile dysfunction. The American Journal of Natural Medicine, vol. 1, no 3, p. 8.
46. Beck V., Rohr U., Jim A. (2005) Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy. J Steroid Biochem Mol Biol, vol. 94, no 5, pp. 499–518.
